الفهرس 
Clinical Relevance Of COX2 And VEGF-A Expression In Disseminated Non Hodgkin’s Lymphoma
IndexOnly 14 pages are availabe for public view
 |  | from | 178 |  |  |
| | | from | 178 | | |
Abstract
Background: NHL comprises 85% of all lymphomas and 3-4% of all cancers around the world. Angiogenesis is required for tumor growth and metastasis, as an important component in the control of cancer progression. Inflammation is an important factor in the cancer phenomenon with COX-2 playing an important role in malignant cell proliferation. Objective: To observe the expression level of the angiogenetic factor VEGF-A, the inflammatory mediator COX-2 in NHL patients and their prognostic relevance. Methods: The patients were recruited from the Medical Oncology Department, National Cancer Institute, Cairo University over a period of 2 years. The methods we used were Immunohistochemical staining for VEGF-A and COX-2 in BMB samples of 40 adult patients with NHL stage IV. Results: The study revealed no significant difference between VEGF-A and COX2 markers expression (positive coexpression 10/40 (25%), negative coexpression 5/40 (12.5%) and single marker expression 25/40 (62.5%)(P=0.09). A statistically significant difference between males (37.5%) and females (6.3%) as regards positive coexpression was found (P=0.025). Although positive coexpression was higher with the lower age group and absence of B symptoms, yet showing statistically non-significant difference (P= 0.072and 0.09 respectively). There was a higher TLC mean and a higher lymphocyte count in the positive VEGF-A expressors versus negative ones, with a non-significant difference (P=0.065). A statistically significant difference between positive coexpressors group with the single positive and the double negative groups regarding TLC (P=0.036) was detected, also higher lymphocyte count among positive coexpressors compared to the other groups, with non-significant difference P=0.077